All issues online, mobile friendly. Works on mobile, tablets & desktop.

For a long time, restoring vision has been like a search for the holy grail for scientists. And for many patients, being diagnosed with a severe retinal disease has meant progressive, irreversible vision loss. However, the past decade has seen some  of the clearest evidence so far that vision loss can be partially restored, not just preserved.

Sweden’s first clinical research center dedicated to ophthalmology has been established at St. Erik Eye Hospital in the Stockholm Region, in collaboration with Karolinska Institutet.

Following Diamyd Medical’s negative results from the March 27 interim analysis of its DIAGNODE-3 study, the Board of Directors has implemented governance changes to strengthen oversight and strategic direction.

Takeda has announced new data, presented at the 2026 American Academy of Dermatology (AAD), from two Phase 3 studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).